Company Filing History:
Years Active: 2007-2008
Title: M. Terrence Howell: Innovator in Selective Inhibition of Cyclooxygenase-2
Introduction
M. Terrence Howell, an accomplished inventor based in Dryden, NY, has made significant contributions to the field of veterinary medicine through his innovative formulations. With a total of two patents to his name, Howell’s work primarily focuses on selectively inhibiting the cyclooxygenase-2 (COX-2) mediated inflammatory response in animals, a breakthrough that can enhance treatment options for various inflammatory conditions.
Latest Patents
Howell's latest patents revolve around complex mixtures that exhibit selective inhibition of COX-2. The formulation is designed to target COX-2-mediated inflammation specifically, offering a potential therapeutic advantage over traditional treatments. These innovative mixtures include an effective amount of component I, chosen from alpha acids and beta acids, alongside at least one component II, sourced from a diverse group that includes essential oils, fats, and waxes. Importantly, component I and II are distinct compounds, ensuring precise targeting of inflammatory pathways. This formulation boasts minimal impact on cyclooxygenase-1, which is vital for protecting the gastric mucosa and maintaining renal function.
Career Highlights
Terrence Howell is currently affiliated with Metaproteomics, LLC, where he collaborates on various projects aimed at advancing understanding in the field of proteomics and inflammatory responses. His contributions to the company have not only led to novel patent applications but have established Howell as a key figure in innovative research and development.
Collaborations
Throughout his career, Howell has partnered with esteemed colleagues, including John G. Babish, to explore groundbreaking approaches to tackle inflammation in animals. Their collaborative efforts have amplified the impact of their research, potentially changing treatment paradigms in veterinary care.
Conclusion
In summary, M. Terrence Howell exemplifies the spirit of innovation in the realm of veterinary medicine. With his focus on selectively inhibiting cyclooxygenase-2, Howell is paving the way for advancements that promise to improve therapeutic outcomes for animals suffering from inflammatory conditions. His work at Metaproteomics, LLC, alongside dedicated collaborators, continues to contribute to the evolving landscape of medical research and development.